Corcept Therapeutics Inc (CORT)
55.96
-0.13
(-0.23%)
USD |
NASDAQ |
Nov 21, 16:00
55.96
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Enterprise Value: 5.496B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 5.496B |
| November 19, 2024 | 5.309B |
| November 18, 2024 | 5.133B |
| November 15, 2024 | 5.050B |
| November 14, 2024 | 5.360B |
| November 13, 2024 | 5.534B |
| November 12, 2024 | 5.675B |
| November 11, 2024 | 5.808B |
| November 08, 2024 | 5.864B |
| November 07, 2024 | 5.309B |
| November 06, 2024 | 5.302B |
| November 05, 2024 | 5.083B |
| November 04, 2024 | 4.865B |
| November 01, 2024 | 4.609B |
| October 31, 2024 | 4.751B |
| October 30, 2024 | 4.533B |
| October 29, 2024 | 4.671B |
| October 28, 2024 | 4.684B |
| October 25, 2024 | 4.573B |
| October 24, 2024 | 4.569B |
| October 23, 2024 | 4.655B |
| October 22, 2024 | 4.742B |
| October 21, 2024 | 4.762B |
| October 18, 2024 | 4.829B |
| October 17, 2024 | 4.559B |
| Date | Value |
|---|---|
| October 16, 2024 | 4.569B |
| October 15, 2024 | 4.524B |
| October 14, 2024 | 4.363B |
| October 11, 2024 | 4.376B |
| October 10, 2024 | 4.357B |
| October 09, 2024 | 4.430B |
| October 08, 2024 | 4.413B |
| October 07, 2024 | 4.296B |
| October 04, 2024 | 4.376B |
| October 03, 2024 | 4.335B |
| October 02, 2024 | 4.421B |
| October 01, 2024 | 4.515B |
| September 30, 2024 | 4.465B |
| September 27, 2024 | 4.117B |
| September 26, 2024 | 4.049B |
| September 25, 2024 | 3.972B |
| September 24, 2024 | 4.125B |
| September 23, 2024 | 4.015B |
| September 20, 2024 | 3.942B |
| September 19, 2024 | 3.803B |
| September 18, 2024 | 3.944B |
| September 17, 2024 | 3.676B |
| September 16, 2024 | 3.547B |
| September 13, 2024 | 3.509B |
| September 12, 2024 | 3.258B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
882.59M
Minimum
Mar 16 2020
5.864B
Maximum
Nov 08 2024
2.184B
Average
2.122B
Median
May 18 2021
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals Inc | 2.080B |
| Madrigal Pharmaceuticals Inc | 6.034B |
| ADMA Biologics Inc | 5.066B |
| Alnylam Pharmaceuticals Inc | 30.33B |
| Akebia Therapeutics Inc | 394.88M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 47.21M |
| Revenue (Quarterly) | 182.55M |
| Total Expenses (Quarterly) | 135.95M |
| EPS Diluted (Quarterly) | 0.41 |
| Gross Profit Margin (Quarterly) | 98.43% |
| Profit Margin (Quarterly) | 25.86% |
| Earnings Yield | 2.25% |
| Operating Earnings Yield | 2.30% |
| Normalized Earnings Yield | 2.252 |